New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation
NCT ID NCT07339839
First seen Jan 20, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tests two drugs, Glecirasib and Ivonescimab, for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C and a protein called PD-L1. The goal is to see if the combination is safe and can shrink tumors. About 42 adults who have not had prior treatment for their advanced cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.